CombinatoRx' Prednisolone/Dipyridamole Combination abstract to be presented at the ACR 2009

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that its abstract entitled, “CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results”, has been accepted for oral presentation at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia on October 20, 2009. The abstract can be accessed online at http://www.rheumatology.org/annual/index.aspwww.eular.org by clicking on "search abstracts" and entering the author name or abstract number.

Oral Presentation:

• Abstract #1943: “CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results,” Huttner, et.al, Tuesday, October 20, 2009: 5:15 PM Room 108 B, Pennsylvania Convention Center.

Source CombinatoRx, Incorporated.